ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 95 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.66 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,271,818 | -44.4% | 2,311,077 | -0.3% | 0.02% | -41.9% |
| Q2 2023 | $22,086,166 | -12.9% | 2,317,541 | +0.5% | 0.04% | -20.4% |
| Q1 2023 | $25,358,696 | +690.5% | 2,305,336 | +1273.7% | 0.05% | +671.4% |
| Q3 2022 | $3,208,000 | +676.8% | 167,816 | +1008.6% | 0.01% | +250.0% |
| Q2 2021 | $413,000 | -91.6% | 15,138 | -91.1% | 0.00% | -90.9% |
| Q1 2021 | $4,903,000 | +120.7% | 169,487 | +114.6% | 0.02% | +83.3% |
| Q4 2020 | $2,222,000 | – | 78,973 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $314,175,000 | 35.62% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $118,583,000 | 20.06% |
| Omega Fund Management, LLC | 844,680 | $25,171,000 | 10.42% |
| Vivo Capital, LLC | 1,686,527 | $50,259,000 | 4.55% |
| Orbimed Advisors | 4,673,850 | $139,281,000 | 2.34% |
| RA Capital Management | 1,165,184 | $34,722,000 | 1.10% |
| Polar Capital LLP | 375,000 | $11,175,000 | 0.12% |
| CAAS CAPITAL MANAGEMENT LP | 22,413 | $668,000 | 0.07% |
| FMR LLC | 5,713,343 | $170,258,000 | 0.02% |
| Laurion Capital Management LP | 50,000 | $1,490,000 | 0.02% |